STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #664 by analyst upside · 2026-06-27
PLRX
Pliant Therapeutics, Inc.
Healthcare · Market Cap $71M · P/E 0x
ANALYST PRICE TARGET
+133.9%
implied upside to consensus target
Current Price $1.14
Consensus Target $2.67
Bull Target $3.0
Bear Target $2.0
Analysts Covering 3
ANALYST CONSENSUS — UNDERPERFORM
Strong Buy
0
Buy
0
Hold
2
Sell
1
52-Week Low $1.09
52-Week High $1.95
YTD Return -8.8%
FUNDAMENTALS
Market Cap $71M
P/E Ratio (TTM) N/A
Forward P/E -1.2x
EPS (TTM) $-1.83
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $1.09
52-Week High $1.95
Current Price $1.14
Bear Target $2.0
Bull Target $3.0
● Now $1.14 ● Target $2.67
TRADING DATA
Avg Volume 488K
YTD Return -8.8%
Analyst Count 3
Consensus Underperform
Upside to Target +133.9%
Last Updated 2026-06-27

ANALYST SUMMARY

Pliant Therapeutics, Inc. (PLRX) is currently trading at $1.14 with a Wall Street consensus price target of $2.67, implying potential upside of 133.9% over the next 12 months. 3 analysts currently cover PLRX, with a consensus rating of Underperform — 0% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $3.0, while the most cautious has a target of $2.0.

PLRX operates in the Healthcare sector with a market capitalisation of $71M. The stock is down 8.8% year-to-date and is currently trading near the lower end of its 52-week range of $1.09 – $1.95.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for PLRX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Canaccord Genuity — Reiterated
Hold → Hold 2026-03-13 Building track record
Piper Sandler — Reiterated
Overweight → Overweight 2026-03-12 14% win rate (7 calls)
RBC Capital — Reiterated
Sector Perform → Sector Perform 2025-11-07 Building track record
JP Morgan ↓ Downgrade
Neutral → Underweight 2025-10-10 43% win rate (7 calls)
Piper Sandler — Reiterated
Overweight → Overweight 2025-08-08 14% win rate (7 calls)
HC Wainwright & Co. reit
Neutral → Neutral 2025-03-18 31% win rate (48 calls)
HC Wainwright & Co. reit
Neutral → Neutral 2025-03-04 31% win rate (48 calls)
Citigroup — Reiterated
Neutral → Neutral 2025-03-04 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
25
out of 100
Coverage depth
11/30
Consensus clarity
12/30
Vote unanimity
0/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →